301 related articles for article (PubMed ID: 18260619)
1. Synthesis and SAR of 2-aryloxy-4-alkoxy-pyridines as potent orally active corticotropin-releasing factor 1 receptor antagonists.
Chen YL; Braselton J; Forman J; Gallaschun RJ; Mansbach R; Schmidt AW; Seeger TF; Sprouse JS; Tingley FD; Winston E; Schulz DW
J Med Chem; 2008 Mar; 51(5):1377-84. PubMed ID: 18260619
[TBL] [Abstract][Full Text] [Related]
2. 2-aryloxy-4-alkylaminopyridines: discovery of novel corticotropin-releasing factor 1 antagonists.
Chen YL; Obach RS; Braselton J; Corman ML; Forman J; Freeman J; Gallaschun RJ; Mansbach R; Schmidt AW; Sprouse JS; Tingley Iii FD; Winston E; Schulz DW
J Med Chem; 2008 Mar; 51(5):1385-92. PubMed ID: 18288792
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of tricyclic imidazo[4,5-b]pyridin-2-ones as corticotropin-releasing factor-1 antagonists.
Guo Z; Tellew JE; Gross RS; Dyck B; Grey J; Haddach M; Kiankarimi M; Lanier M; Li BF; Luo Z; McCarthy JR; Moorjani M; Saunders J; Sullivan R; Zhang X; Zamani-Kord S; Grigoriadis DE; Crowe PD; Chen TK; Williams JP
J Med Chem; 2005 Aug; 48(16):5104-7. PubMed ID: 16078829
[TBL] [Abstract][Full Text] [Related]
4. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
Chen C; Wilcoxen KM; Huang CQ; Xie YF; McCarthy JR; Webb TR; Zhu YF; Saunders J; Liu XJ; Chen TK; Bozigian H; Grigoriadis DE
J Med Chem; 2004 Sep; 47(19):4787-98. PubMed ID: 15341493
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of tricyclic corticotropin-releasing factor-1 antagonists.
Gross RS; Guo Z; Dyck B; Coon T; Huang CQ; Lowe RF; Marinkovic D; Moorjani M; Nelson J; Zamani-Kord S; Grigoriadis DE; Hoare SR; Crowe PD; Bu JH; Haddach M; McCarthy J; Saunders J; Sullivan R; Chen T; Williams JP
J Med Chem; 2005 Sep; 48(18):5780-93. PubMed ID: 16134945
[TBL] [Abstract][Full Text] [Related]
6. Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine core.
Dyck B; Grigoriadis DE; Gross RS; Guo Z; Haddach M; Marinkovic D; McCarthy JR; Moorjani M; Regan CF; Saunders J; Schwaebe MK; Szabo T; Williams JP; Zhang X; Bozigian H; Chen TK
J Med Chem; 2005 Jun; 48(12):4100-10. PubMed ID: 15943483
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of 2-anilino-3-phenylsulfonyl-6-methylpyridines as corticotropin-releasing factor1 receptor ligands.
Hartz RA; Arvanitis AG; Arnold C; Rescinito JP; Hung KL; Zhang G; Wong H; Langley DR; Gilligan PJ; Trainor GL
Bioorg Med Chem Lett; 2006 Feb; 16(4):934-7. PubMed ID: 16297619
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, structure-activity relationships, and in vivo properties of 3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-ones as corticotropin-releasing factor-1 receptor antagonists.
Dzierba CD; Takvorian AG; Rafalski M; Kasireddy-Polam P; Wong H; Molski TF; Zhang G; Li YW; Lelas S; Peng Y; McElroy JF; Zaczek RC; Taub RA; Combs AP; Gilligan PJ; Trainor GL
J Med Chem; 2004 Nov; 47(23):5783-90. PubMed ID: 15509177
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists.
Hartz RA; Ahuja VT; Arvanitis AG; Rafalski M; Yue EW; Denhart DJ; Schmitz WD; Ditta JL; Deskus JA; Brenner AB; Hobbs FW; Payne J; Lelas S; Li YW; Molski TF; Mattson GK; Peng Y; Wong H; Grace JE; Lentz KA; Qian-Cutrone J; Zhuo X; Shu YZ; Lodge NJ; Zaczek R; Combs AP; Olson RE; Bronson JJ; Mattson RJ; Macor JE
J Med Chem; 2009 Jul; 52(14):4173-91. PubMed ID: 19552437
[TBL] [Abstract][Full Text] [Related]
10. Novel derivatives of 2-pyridinemethylamine as selective, potent, and orally active agonists at 5-HT1A receptors.
Vacher B; Bonnaud B; Funes P; Jubault N; Koek W; Assié MB; Cosi C; Kleven M
J Med Chem; 1999 May; 42(9):1648-60. PubMed ID: 10229633
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and structure-activity relationships of novel pyrazolo[5,1-b]thiazole derivatives as potent and orally active corticotropin-releasing factor 1 receptor antagonists.
Takahashi Y; Hashizume M; Shin K; Terauchi T; Takeda K; Hibi S; Murata-Tai K; Fujisawa M; Shikata K; Taguchi R; Ino M; Shibata H; Yonaga M
J Med Chem; 2012 Oct; 55(19):8450-63. PubMed ID: 22971011
[TBL] [Abstract][Full Text] [Related]
12. Discovery of N-(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist.
Hodgetts KJ; Ge P; Yoon T; De Lombaert S; Brodbeck R; Gulianello M; Kieltyka A; Horvath RF; Kehne JH; Krause JE; Maynard GD; Hoffman D; Lee Y; Fung L; Doller D
J Med Chem; 2011 Jun; 54(12):4187-206. PubMed ID: 21618986
[TBL] [Abstract][Full Text] [Related]
13. Receptor occupancy of nonpeptide corticotropin-releasing factor 1 antagonist DMP696: correlation with drug exposure and anxiolytic efficacy.
Li YW; Hill G; Wong H; Kelly N; Ward K; Pierdomenico M; Ren S; Gilligan P; Grossman S; Trainor G; Taub R; McElroy J; Zazcek R
J Pharmacol Exp Ther; 2003 Apr; 305(1):86-96. PubMed ID: 12649356
[TBL] [Abstract][Full Text] [Related]
14. An orally active corticotropin releasing factor 1 receptor antagonist from 8-aryl-1,3a,7,8-tetraaza-cyclopenta[a]indenes.
Han X; Civiello R; Pin SS; Burris K; Balanda LA; Knipe J; Ren S; Fiedler T; Browman KE; Macci R; Taber MT; Zhang J; Dubowchik GM
Bioorg Med Chem Lett; 2007 Apr; 17(7):2026-30. PubMed ID: 17258456
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and pharmacological characterization of novel druglike corticotropin-releasing factor 1 antagonists.
Di Fabio R; St-Denis Y; Sabbatini FM; Andreotti D; Arban R; Bernasconi G; Braggio S; Blaney FE; Capelli AM; Castiglioni E; Di Modugno E; Donati D; Fazzolari E; Ratti E; Feriani A; Contini S; Gentile G; Ghirlanda D; Provera S; Marchioro C; Roberts KL; Mingardi A; Mattioli M; Nalin A; Pavone F; Spada S; Trist DG; Worby A
J Med Chem; 2008 Dec; 51(23):7370-9. PubMed ID: 18989952
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of a novel nonpeptide antagonist radioligand, (+/-)-N-[2-methyl-4-methoxyphenyl]-1-(1-(methoxymethyl) propyl)-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine ([3H]SN003) for corticotropin-releasing factor1 receptors.
Zhang G; Huang N; Li YW; Qi X; Marshall AP; Yan XX; Hill G; Rominger C; Prakash SR; Bakthavatchalam R; Rominger DH; Gilligan PJ; Zaczek R
J Pharmacol Exp Ther; 2003 Apr; 305(1):57-69. PubMed ID: 12649353
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.
Gilligan PJ; Clarke T; He L; Lelas S; Li YW; Heman K; Fitzgerald L; Miller K; Zhang G; Marshall A; Krause C; McElroy JF; Ward K; Zeller K; Wong H; Bai S; Saye J; Grossman S; Zaczek R; Arneric SP; Hartig P; Robertson D; Trainor G
J Med Chem; 2009 May; 52(9):3084-92. PubMed ID: 19361209
[TBL] [Abstract][Full Text] [Related]
18. Rational design, synthesis, and structure-activity relationships of aryltriazoles as novel corticotropin-releasing factor-1 receptor antagonists.
Lowe RF; Nelson J; Dang TN; Crowe PD; Pahuja A; McCarthy JR; Grigoriadis DE; Conlon P; Saunders J; Chen C; Szabo T; Chen TK; Bozigian H
J Med Chem; 2005 Mar; 48(5):1540-9. PubMed ID: 15743196
[TBL] [Abstract][Full Text] [Related]
19. Dihydropyrrole[2,3-d]pyridine derivatives as novel corticotropin-releasing factor-1 antagonists: mapping of the receptor binding pocket by in silico docking studies.
Di Fabio R; Arban R; Bernasconi G; Braggio S; Blaney FE; Capelli AM; Castiglioni E; Donati D; Fazzolari E; Ratti E; Feriani A; Contini S; Gentile G; Ghirlanda D; Sabbatini FM; Andreotti D; Spada S; Marchioro C; Worby A; St-Denis Y
J Med Chem; 2008 Nov; 51(22):7273-86. PubMed ID: 18975927
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of 1,2,3,7-tetrahydro-6h-purin-6-one and 3,7-dihydro-1h-purine-2,6-dione derivatives as corticotropin-releasing factor(1) receptor antagonists.
Hartz RA; Nanda KK; Ingalls CL; Ahuja VT; Molski TF; Zhang G; Wong H; Peng Y; Kelley M; Lodge NJ; Zaczek R; Gilligan PJ; Trainor GL
J Med Chem; 2004 Sep; 47(19):4741-54. PubMed ID: 15341489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
